MyStreetHealth

Opioid Addiction Treatment
with Buprenorphine

ONLINE
Suboxone Clinic

OUR TREATMENT APPROACH

MyStreetHealth and "Medication First"

image1

  • Patients receive buprenorphine medication as quickly as possible, prior to lengthy assessments or treatment planning sessions. 
  • Buprenorphine medication management is delivered without arbitrary tapering or time limits.
  • Psychosocial services are continually offered but not required as a condition of buprenorphine medication management.
  • Buprenorphine is discontinued only if it is worsening the patient's condition.


"Medication First" is Not "Medication Only"

image2

  • Our "Medication First" approach provides an important stabilizing resource, FDA-approved and evidence-based  Buprenorphine, without conditioning the receipt of medication on other service requirements. 
  • However, everyone is offered psychosocial support. 
  • Once stable on medication, one may choose to re-engage in normal life activities rather than invest hours per day or week in group therapy and education. 
  • "Medication First" is consistent with the Substance Abuse and Mental Health Services Administration's (SAMHSA) working definition of recovery which prioritizes this form of self-determination: 
  • Recovery is a process of change through which individuals improve their health and wellness, live a self-directed life, and strive to reach their full potential. 


MyStreetHealth has "Do's and Don'ts"

image3

  • We DO NOT initiate a taper or discontinue buprenorphine in response to patient non-adherence (e.g., missing sessions).
  • We DO NOT mandate participation in individual or group counseling as a requirement for continued buprenorphine medication management.
  • We DO NOT set a time limit for buprenorphine treatment.
  • We DO NOT encourage rapid buprenorphine taper protocols with the goal of transitioning to antagonist medications or no medications. 
  • We DO NOT discharge a patient for a positive drug test result. 
  • We DO individualize dose decisions based on individual patient factors, particularly craving intensity and environmental support.
  • We DO increase client accountability measures (e.g., drug testing, frequency of medication or dosing visits) without discontinuing buprenorphine if adherence to treatment protocols are disrupted by several missed visits or positive urines. 
  • We DO clarify the rationale for recommending psychosocial supports. 

*Adapted from MissouriOpioidSTR.org/treatment